Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Abroad (travel likely)RecruitingPHASE2

Conditions

Acute Lymphoblastic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Jin Wang, PhD) · jinwang@shsmu.edu.cn · +86 13524945202

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma

Abroad (travel likely)RecruitingPHASE2

Charlotte, United States · Tulsa, United States

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Jacksonville, United States

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

B-NHL · B-Non Hodgkin Lymphoma · Acute Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States